New drug combo targets Hard-to-Treat cancers in early trial
NCT ID NCT06422520
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a new drug called BGB-C354, alone or with an immunotherapy (tislelizumab), in 63 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety and find the right dose. Researchers also looked for signs that the tumors shrank. The study is complete, but results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BGB-C354 (an antibody-drug conjugate) and tislelizumab (an immunotherapy)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early, first-in-human study with only 63 participants. The drug may not shrink tumors or could cause serious side effects. Success in this small trial does not guarantee it will work in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215-5418, United States
-
Florida Cancer Specialist Research Institute Lake Nona
Orlando, Florida, 32827-7400, United States
-
Hubei Cancer Hospital
Wuhan, Hubei, 430079, China
-
Jilin Cancer Hospital
Changchun, Jilin, 130021, China
-
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, 110042, China
-
Next Oncology
San Antonio, Texas, 78229-6028, United States
-
One Clinical Research
Nedlands, Western Australia, WA 6009, Australia
-
St Vincents Hospital Melbourne
Fitzroy, Victoria, VIC 3065, Australia
-
The Alfred Hospital
Melbourne, Victoria, VIC 3004, Australia
-
The University of Texas Md Anderson Cancer Center
Houston, Texas, 77030-4009, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110-1010, United States
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
-
Westmead Hospital
Westmead, New South Wales, NSW 2145, Australia